Nabaxor (Rivaroxaban)

Rivaroxaban, the active ingredient in Nabaxor, is a Direct Factor Xa Inhibitor presented as an oral dosage form for oral use. It is indicated for the prevention of stroke in non‑valvular atrial fibrillation and for the treatment and prevention of venous thromboembolism in adults.

GNH USA supplies Nabaxor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rivaroxaban is used across several thrombo‑embolic conditions, acting on the coagulation cascade to reduce clot formation.

- Non‑valvular atrial fibrillation: lowers risk of stroke and systemic embolism. - Deep vein thrombosis (DVT): treats acute clot formation and promotes resolution. - Pulmonary embolism (PE): provides therapeutic anticoagulation for acute events. - Post‑operative hip or knee replacement: prevents postoperative DVT and PE.

Rivaroxaban may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Bleeding: nosebleeds, gum bleeding, or prolonged bruising. - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache or dizziness. - Anemia due to blood loss. - Fatigue or weakness.

Serious or Rare Side Effects: - Intracranial hemorrhage. - Spinal or epidural hematoma, especially after neuraxial procedures. - Severe allergic reactions (anaphylaxis, angioedema). - Hepatic injury indicated by elevated transaminases. - Thrombocytopenia. - Myocardial infarction.

Before initiating rivaroxaban therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

- Renal function assessment: adjust use in severe impairment. - Bleeding risk evaluation: avoid in active pathological bleeding. - Concomitant antiplatelet therapy: monitor closely for additive bleeding. - Elderly patients: consider dose adjustments and increased surveillance. - Drug interactions: review all concomitant medications for CYP3A4 and P‑gp effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Rivaroxaban interacts with several drug classes that can alter its anticoagulant effect. Understanding the level of interaction helps guide clinical decisions.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, heparin): markedly increased bleeding risk. - Strong CYP3A4 and P‑gp inhibitors (e.g., ketoconazole, ritonavir): may raise plasma concentrations. - Antiplatelet agents (e.g., clopidogrel, aspirin): additive hemorrhagic risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can increase gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: may enhance bleeding tendency. - Certain antifungals (e.g., fluconazole) and antibiotics (e.g., erythromycin): moderate CYP3A4 inhibition. - Herbal supplements such as St. John’s wort: may reduce efficacy via enzyme induction. - Vitamin K antagonists: require careful INR monitoring if co‑administered.